Core Viewpoint - Meiz Health (02415.HK) anticipates a significant increase in shareholder profit for the six months ending June 30, 2025, projecting at least RMB 10 million, compared to a mere RMB 200,000 for the same period in 2024 [1] Group 1: Profit Forecast - The company expects a substantial rise in profit primarily due to the recovery in the pharmaceutical industry [1] - The shift towards evidence-driven marketing models among domestic pharmaceutical companies is driving demand for precise omnichannel marketing solutions [1] - The application of artificial intelligence is enhancing production efficiency across various business segments [1] - The active implementation of environmental, social, and governance (ESG) principles is leading to more effective control of operational costs [1]